Percutaneous ablation of malignant and locally aggressive solid tumors in pediatric patients
Abstract
Image-guided percutaneous ablation is an accepted treatment modality for common adult cancers. Unfortunately, its use in patients younger than 18 years is rare. This retrospective review presents our series of pediatric patients treated with ablation at our institution. From January 2002 to December 2021, a total of 14 patients (17 lesions) younger than 18 years were treated with percutaneous image-guided ablation. Estimated overall survival at 5 years was 58%; median survival of this group was not reached. Estimated local tumor progression-free survival at 5 years was 62%. One major complication was recorded.
CONFLICT OF INTEREST
SBS: Grants from GE Health Care, Jonhnson & Jonhson, Elesta and Angiodynamics. Consultant for Var JPE: Advisory board AztraZeneca. The authors declare that there is no conflict of interest.
